Eisai

Japan-based Eisai has opened a new global potent packaging facility for its investigational compound, lenvatinib, at the EMEA Knowledge Centre (EKC) in Hatfield, UK.

The new facility will handle the packaging of lenvatinib, which is being developed to treat advanced thyroid cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Featuring hybrid packaging lines, the packaging facility was developed to cope with highly potent and difficult-to-handle compounds.

UK Life Sciences minister and MP George Freeman said: "Pharmaceuticals manufacturing is important to our economy, with more than £22bn worth of exports in 2013 and a positive trade balance of just over £2bn."

The new two-storey 2,900m² facility is said to expand the current Hatfield site by 40%, and includes the firm’s EMEA headquarters, which serves as a global supply centre of excellence for key products.

See Also:

Eisai invested £150m in the Hatfield site, which holds the capacity to produce 450 million tablets in ten million packs each year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Discovered and developed by Eisai, lenvatinib received orphan drug designation from European Commission in 2013, to treat follicular and papillary thyroid cancer."

In June 2009, Eisai opened the £100m EKC in Hatfield, integrating the firm’s discovery research, clinical development, production and marketing.

Eisai CEO Haruo Naito said: "The UK is an ideal location for advanced manufacturing.

"We are committed to the life sciences industry in this country and it will continue to play a pivotal role in our commercial growth strategy."

Discovered and developed by Eisai, lenvatinib received orphan drug designation from European Commission in 2013, to treat follicular and papillary thyroid cancer.

Eisai submitted regulatory applications for the drug in the US, EU and Japan, while the European Medicines Agency accepted a request for accelerated approval of lenvatinib for advanced thyroid cancer.

Image: Eisai head office, Tokyo. Photo: courtesy of KW at ja.wikipedia.